Takashi Owa
Corporate Officer/Principal presso EISAI CO., LTD.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Haruo Naito | M | 76 | 49 anni | |
| Yasushi Okada | M | 65 | 43 anni | |
| Ping Zhu | M | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | 12 anni |
| Sayoko Sasaki | F | 55 | 33 anni | |
| Keisuke Naito | M | 35 | 11 anni | |
| Masatomi Akana | M | 57 | 34 anni | |
| Tatsuyuki Yasuno | M | 56 | 33 anni | |
| Kenta Takahashi | M | 64 | 41 anni | |
| Clive Richard Thornley | M | 59 | 2 anni | |
| Ryota Miura | M | 50 | 3 anni | |
| Lynn Kramer | M | 73 | 15 anni | |
| Teruyuki Masaka | M | 46 | 23 anni | |
| Yoshiteru Kato | M | 64 | 36 anni | |
| Fumihiko Ike | M | 72 | 3 anni | |
| Hiroyuki Kato | M | 66 | 42 anni | |
| Yumiko Miwa | F | 58 | 4 anni | |
| Yasunobu Kai | M | 62 |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | - |
| Makoto Hoketsu | M | - | - | |
| Mitsuru Shomon | M | - | - | |
| Brian Liau | M | - |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | - |
| Alexander Scott | M | - |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | - |
| Toshitaka Asano | M | 58 | - | |
| Toru Moriyama | M | 69 | - | |
| Terushige Iike | M | 60 | 38 anni | |
| Richard C. Woodman | M | 69 |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | 2 anni |
| Shohei Kanazawa | M | 59 | 36 anni | |
| Gary Bryan Hendler | M | 57 | 14 anni | |
| Yuko Yasuda | F | 62 | - | |
| Ivan Cheung | M | 47 | 19 anni | |
| Akiko Nakahama | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Giappone | 70 | 93.33% |
| Stati Uniti | 5 | 6.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Takashi Owa
- Contatti personali
